Phaseline

Companies › Medicure

Medicure: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pyridoxal Phosphate
Pyridoxal 5'-phosphate (active form of vitamin B6) cofactor replacement for PNPO deficienc
PNPOPhase 3Pyridox(am)Ine 5'-Phosphate Oxidase DeficiencySep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04706013Pyridoxal PhosphatePhase 3Pyridox(am)Ine 5'-Phosphate Oxidase DeficiencyMetabolic and endocrineSep 2027

From the company's SEC filings

Cash of 7m CAD on 2024-12-31; operating cash flow positive

Targets

PNPO (1)

Companies with the same targets

–

Companies built like this

vTv Therapeutics Calcilytix Therapeutics, Inc., a BridgeBio company Fresenius Kabi Renibus Therapeutics Chendu DIAO Pharmaceutical Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.